Computational approaches to modeling drug transporters

C Chang, PW Swaan - European Journal of Pharmaceutical Sciences, 2006 - Elsevier
Computational modeling has advanced our understanding of drug absorption, tissue
distribution, excretion and toxicity profiles by providing both direct and indirect knowledge of …

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

KS Fenner, HM Jones, M Ullah, S Kempshall… - Xenobiotica, 2012 - Taylor & Francis
Over the last two decades the impact on drug pharmacokinetics of the organic anion
transporting polypeptides (OATPs: OATP-1B1, 1B3 and 2B1), expressed on the sinusoidal …

Transport vs. metabolism: what determines the pharmacokinetics and pharmacodynamics of drugs? Insights from the extended clearance model

G Patilea‐Vrana, JD Unadkat - Clinical Pharmacology & …, 2016 - Wiley Online Library
The well‐stirred hepatic clearance model (WSHM) has been expanded to include drug
transporters (ie, extended clearance model [ECM]). However, the consequences of this …

Identification and evaluation of clinical substrates of organic anion transporting polypeptides 1B1 and 1B3

SJ McFeely, TK Ritchie, J Yu… - Clinical and …, 2019 - Wiley Online Library
Organic anion transporting polypeptides (OATPs) 1B1 and 1B3 facilitate the uptake of drugs
and endogenous compounds into the liver. In recent years, the impact of these transporters …

[HTML][HTML] A mechanistic framework for in vitro–in vivo extrapolation of liver membrane transporters: prediction of drug–drug interaction between rosuvastatin and …

M Jamei, F Bajot, S Neuhoff, Z Barter, J Yang… - Clinical …, 2014 - Springer
Abstract Background and Objectives The interplay between liver metabolising enzymes and
transporters is a complex process involving system-related parameters such as liver blood …

PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism

J Fan, S Chen, E CY Chow… - Current drug …, 2010 - ingentaconnect.com
Experimental strategies have long been applied for in vitro or in vivo evaluation of the effect
of transporters and/or enzymes on the bioavailability. However, the lack of specific inhibitors …

Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug …

X Liang, Y Lai - Expert Opinion on Drug Metabolism & Toxicology, 2021 - Taylor & Francis
Introduction: Human pharmacokinetic (PK) prediction can be a significant challenge to drug
candidates undergoing transporter-mediated clearance, when only animal data and in vitro …

Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms

K Yoshida, K Maeda, Y Sugiyama - Annual review of …, 2013 - annualreviews.org
Recent studies of membrane transporters have revealed their importance in determining the
pharmacokinetics of transporter substrates. When drug-drug interactions (DDIs) or genetic …

The presence of a transporter-induced protein binding shift: a new explanation for protein-facilitated uptake and improvement for in vitro-in vivo extrapolation

CM Bowman, H Okochi, LZ Benet - Drug Metabolism and Disposition, 2019 - ASPET
Accurately predicting hepatic clearance is an integral part of the drug-development process,
and yet current in vitro to in vivo (IVIVE) extrapolation methods yield poor predictions …

In vitro evidence for the role of OATP and OCT uptake transporters in drug–drug interactions

J Kindla, MF Fromm, J König - Expert opinion on drug metabolism …, 2009 - Taylor & Francis
Background: Transport proteins, for example the drug export pump P-glycoprotein, are
important for the absorption, distribution and excretion of drugs. Inhibition and induction of P …